Amgen Submits Application to Expand Indication for XGEVA to Prevent or Delay Spread of Prostate Cancer to the Bone

Amgen

today announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, XGEVA would be the first therapy licensed to prevent or delay the spread of cancer to the bone.